03:45 PM EST - Resverlogix Corp. : announced today that its lead drug RVX-208, a first in class ApoA-I production drug, illustrated positive effects on an important cognitive function and Alzheimer's Disease (AD) marker, plasma Amyloid beta 40 (Aß40). This analysis was performed based on increasing evidence in the literature that the transport of potentially harmful Aß40 from the brain to the general circulatory system may be beneficial. Resverlogix Corp.
shares T.RVX are trading up $0.21 at $2.26.
